Last reviewed · How we verify

Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older — Treatment Landscape & Competitive Intelligence

Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
FLOVENT 500mcg FLOVENT 500mcg GlaxoSmithKline Inhaled corticosteroid (ICS) Glucocorticoid receptor (GR)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. GlaxoSmithKline · 1 drug in Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older:

Cite this brief

Drug Landscape (2026). Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/maintenance-treatment-of-asthma-as-prophylactic-therapy-in-patients-aged-4-years-and-older. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing